Synergistic Combination Regimens
Solid Tumors
Not DisclosedResearch
Key Facts
About Crescent Biopharma
Crescent Biopharma is a public, clinical-stage biotechnology company with a mission to transform cancer treatment by capitalizing on three major paradigm shifts: next-generation immuno-oncology, improved antibody-drug conjugates (ADCs), and synergistic combination therapies. Founded in 2018 and led by a seasoned team with deep oncology development expertise, the company is advancing a pipeline of novel therapies for solid tumors. Its strategy focuses on applying validated modalities to well-characterized targets to de-risk development and accelerate the delivery of high-impact medicines.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |